| Autor: |
Kawada Y; Department of Urology, Gifu University School of Medicine, Japan., Lee JM, Saito I, Lai C, Chang LS, Limson BM, Polnikorn N, Daili SF |
| Jazyk: |
angličtina |
| Zdroj: |
Arzneimittel-Forschung [Arzneimittelforschung] 1990 Feb; Vol. 40 (2 Pt 1), pp. 190-2. |
| Abstrakt: |
Ofloxacin, a new quinolone antibacterial agent, is active in vitro against gonococcal and nongonococcal urogenital pathogens. Chlamydia trachomatis infection is the most common cause of nongonococcal urethritis. In a multicenter study in seven Asian countries, 105 mal patients with chlamydial urethritis and 46 male patients with nongonococcal and nonchlamydial urethritis were treated with oral ofloxacin at a dosage of 200 mg twice daily for 5 to 10 days. The evaluation performed at day 5 and/or day 10 after treatment revealed good results in 58.2% and 96.8% of the chlamydial urethritis group, and 73.1% and 79.4% of the nongonococcal, nonchlamydial urethritis group, respectively. No severe side effects were observed. Ten-day treatment with ofloxacin showed good clinical efficacy on nongonococcal urethritis. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
